The North America Live Biotherapeutic Products And Microbiome CDMO Market would witness market growth of 41.7% CAGR during the forecast period (2023-2029).
Living organisms, like viruses or bacteria, are utilized in live biotherapeutic products to cure or prevent disease. The US FDA describes live biotherapeutic products as biological products that are live organism-containing, such as bacteria. LBPs should be applicable to the prevention, cure, or treatment of a human disease or condition and should not be a vaccine. LBPs are not oncolytic bacteria, filterable viruses, or products designed to be gene therapy agents. They are also not supplied via injection. For example, an LBP might be a strain or strain of lactobacilli given orally to individuals with ulcerative colitis or given intravaginally in order to avoid bacterial vaginosis. Recombinant LBPs are live biotherapeutic products made of microorganisms that have undergone genetic mutation, such as the deliberate insertion, deletion, or alteration of genetic information.
A deeper knowledge of the significance of microbes in maintaining and sustaining critical physiological processes of the host has emerged in biomedical science during the last several decades, changing the perspective from one in which all microorganisms are viewed as health hazards. On the contrary, the microbiome is crucial for human health, and changes to its composition, relative abundances, or elements can result in disease. This is now a well-accepted fact. Therefore, it is crucial to comprehend this microbiome-host link in order to affect the microbiome with the goal of maintaining or enhancing health. Furthermore, the discovery of novel microbial strains and/or microbial functions helpful in the development of future preventative or therapeutic applications has been made possible by large-scale research efforts like Meta Hit and the Human Microbiome Project.
The region also has a high prevalence of C.difficile. Major health risks are posed by C. diff. 12,800 fatalities and an estimated 223,900 hospitalized patient cases were reported in the United States in 2017, as reported by the CDC. The advent of the infectious strain ribotype 027 was a major factor in the rise in Clostridioides difficile infection and related hospitalizations in the 2000s. The development of improved diagnostic tests for C. difficile in the latter half of the early 2000s, like nucleic acid amplification tests (NAATs), is most likely to blame for the increase in the frequency of infections that are caused by C. difficile. Consequently, government-initiated R&D and monitoring programs have increased in the region. Hence, the region presents lucrative growth prospects for the regional market throughout the forecast period.
The US market dominated the North America Live Biotherapeutic Products And Microbiome CDMO Market by Country in 2022, thereby, achieving a market value of $80,668.6 Thousands by 2029. The Canada market is showcasing a CAGR of 44.9% during (2023 - 2029). Additionally, The Mexico market would register a CAGR of 43.6% during (2023 - 2029).
Based on Application, the market is segmented into C.difficile, Crohns Disease, IBS, Diabetes, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Worldwide Live Biotherapeutic Products And Microbiome CDMO Market is Projected to reach USD 159.1 Million by 2029, at a CAGR of 42.5%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Arranta Bio Holdings, LLC (Recipharm AB) (EQT AB), Cerbios-Pharma SA, Biose Industrie, List Biological Laboratories, Inc., AcuraBio Pty Ltd (Ampersand Capital Partners), Wacker Chemie AG (Dr. Alexander Wacker Familiengesellschaft mbH), Quay Pharmaceuticals Ltd (SGS S.A.), BiomX, Inc., Lonza Group AG, and 4D Pharma Plc.
Scope of the Study
Market Segments Covered in the Report:
By Application
- C.difficile
- Crohns Disease
- IBS
- Diabetes
- Others
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Arranta Bio Holdings, LLC (Recipharm AB) (EQT AB)
- Cerbios-Pharma SA
- Biose Industrie
- List Biological Laboratories, Inc.
- AcuraBio Pty Ltd (Ampersand Capital Partners)
- Wacker Chemie AG (Dr. Alexander Wacker Familiengesellschaft mbH)
- Quay Pharmaceuticals Ltd (SGS S.A.)
- BiomX, Inc.
- Lonza Group AG
- 4D Pharma Plc
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Live Biotherapeutic Products And Microbiome CDMO Market, by Application
1.4.2 North America Live Biotherapeutic Products And Microbiome CDMO Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. North America Live Biotherapeutic Products And Microbiome CDMO Market by Application
3.1 North America C.difficile Market by Country
3.2 North America Crohns Disease Market by Country
3.3 North America IBS Market by Country
3.4 North America Diabetes Market by Country
3.5 North America Others Market by Country
Chapter 4. North America Live Biotherapeutic Products And Microbiome CDMO Market by Country
4.1 US Live Biotherapeutic Products And Microbiome CDMO Market
4.1.1 US Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.2 Canada Live Biotherapeutic Products And Microbiome CDMO Market
4.2.1 Canada Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.3 Mexico Live Biotherapeutic Products And Microbiome CDMO Market
4.3.1 Mexico Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.4 Rest of North America Live Biotherapeutic Products And Microbiome CDMO Market
4.4.1 Rest of North America Live Biotherapeutic Products And Microbiome CDMO Market by Application
Chapter 5. Company Profiles
5.1 Arranta Bio Holdings, LLC (Recipharm AB) (EQT AB)
5.1.1 Company Overview
5.1.2 Financial Analysis
5.1.3 Segmental and Regional Analysis
5.1.4 Recent strategies and developments:
5.1.4.1 Acquisition and Mergers:
5.1.4.2 Geographical Expansions:
5.2 Cerbios-Pharma SA
5.2.1 Company Overview
5.3 Biose Industrie
5.3.1 Company Overview
5.3.2 Recent strategies and developments:
5.3.2.1 Geographical Expansions:
5.4 List Biological Laboratories, Inc.
5.4.1 Company Overview
5.5 AcuraBio Pty Ltd (Ampersand Capital Partners)
5.5.1 Company Overview
5.6 Wacker Chemie AG (Dr. Alexander Wacker Familiengesellschaft mbH)
5.6.1 Company Overview
5.6.2 Financial Analysis
5.6.3 Segmental and Regional Analysis
5.6.4 Research & Development Expenses
5.7 Quay Pharmaceuticals Ltd (SGS S.A.)
5.7.1 Company Overview
5.7.2 Financial Analysis
5.7.3 Segmental Analysis
5.7.4 Recent strategies and developments:
5.7.4.1 Partnerships, Collaborations, and Agreements:
5.8 BiomX, Inc.
5.8.1 Company Overview
5.8.2 Research & Development Expenses
5.9 Lonza Group AG
5.9.1 Company Overview
5.9.2 Financial Analysis
5.9.3 Segmental and Regional Analysis
5.9.4 Research & Development Expenses
5.9.5 Recent strategies and developments:
5.9.5.1 Acquisition, Joint Ventures, and Mergers:
5.10. 4D Pharma Plc
5.10.1 Company Overview
5.10.2 Financial Analysis
5.10.3 Research & Development Expense
TABLE 1 North America Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
TABLE 2 North America Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
TABLE 3 North America Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
TABLE 4 North America Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
TABLE 5 North America C.difficile Market by Country, 2019 - 2022, USD Thousands
TABLE 6 North America C.difficile Market by Country, 2023 - 2029, USD Thousands
TABLE 7 North America Crohns Disease Market by Country, 2019 - 2022, USD Thousands
TABLE 8 North America Crohns Disease Market by Country, 2023 - 2029, USD Thousands
TABLE 9 North America IBS Market by Country, 2019 - 2022, USD Thousands
TABLE 10 North America IBS Market by Country, 2023 - 2029, USD Thousands
TABLE 11 North America Diabetes Market by Country, 2019 - 2022, USD Thousands
TABLE 12 North America Diabetes Market by Country, 2023 - 2029, USD Thousands
TABLE 13 North America Others Market by Country, 2019 - 2022, USD Thousands
TABLE 14 North America Others Market by Country, 2023 - 2029, USD Thousands
TABLE 15 North America Live Biotherapeutic Products And Microbiome CDMO Market by Country, 2019 - 2022, USD Thousands
TABLE 16 North America Live Biotherapeutic Products And Microbiome CDMO Market by Country, 2023 - 2029, USD Thousands
TABLE 17 US Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
TABLE 18 US Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
TABLE 19 US Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
TABLE 20 US Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
TABLE 21 Canada Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
TABLE 22 Canada Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
TABLE 23 Canada Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
TABLE 24 Canada Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
TABLE 25 Mexico Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
TABLE 26 Mexico Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
TABLE 27 Mexico Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
TABLE 28 Mexico Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
TABLE 29 Rest of North America Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
TABLE 30 Rest of North America Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
TABLE 31 Rest of North America Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
TABLE 32 Rest of North America Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
TABLE 33 Key Information – Arranta Bio Holdings, LLC
TABLE 34 Key Information – Cerbios-Pharma SA
TABLE 35 Key Information – Biose Industrie
TABLE 36 Key Information – List Biological Laboratories, Inc.
TABLE 37 Key Information – AcuraBio Pty Ltd
TABLE 38 Key Information – Wacker Chemie AG
TABLE 39 Key Information – Quay Pharmaceuticals Ltd
TABLE 40 Key Information – BiomX, Inc.
TABLE 41 Key Information – Lonza Group AG
TABLE 42 Key Information – 4D Pharma Plc
List of Figures
FIG 1 Methodology for the research
FIG 2 North America Live Biotherapeutic Products And Microbiome CDMO Market share by Application, 2022
FIG 3 North America Live Biotherapeutic Products And Microbiome CDMO Market share by Application, 2029
FIG 4 North America Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2029, USD Thousands
FIG 5 North America Live Biotherapeutic Products And Microbiome CDMO Market share by Country, 2022
FIG 6 North America Live Biotherapeutic Products And Microbiome CDMO Market share by Country, 2029
FIG 7 North America Live Biotherapeutic Products And Microbiome CDMO Market by Country, 2019 - 2029, USD Thousands